Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Accuray acquires TomoTherapy

Accuray Incorporated announced today that it has completed its previously announced acquisition of TomoTherapy Incorporated.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. A new partnership facilitated by SAIC-Frederick Inc. aims to help change that outcome.

13 Jun 2011

Scientists identify potential target for reversing deadly blood infection sepsis

By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

13 Jun 2011

IASLC releases interactive staging tool in thoracic oncology

The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.

13 Jun 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Spanish scale measures concern about cancer in healthy people

When a person has a family history of cancer, their worry about developing the disease may lead to them refusing to have preventive tests. Advice from genetic counselling units reduces their anxiety but, until now, nobody knew how much. Now, a scientific team has validated the 'Escala de Preocupaci-n por el C-ncer - EPC' (equivalent of the Cancer Worry Scale), the first of its kind in the Spanish language, in order to evaluate it.

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients.

10 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

Accuray receives shareholders approval to acquire TomoTherapy

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated by Accuray.

10 Jun 2011

Drugs for enlarged prostate raise cancer risk

According to health officials, this Thursday, a class of drugs meant to improve symptoms of an enlarged prostate gland may actually increase the chance of getting a more serious form of prostate cancer. However they also said the drugs' benefits outweigh the risks.

9 Jun 2011

Avvo.com, cites top 10 most popular medical specialty categories based on website's patient usage

Avvo (www.avvo.com), the world's largest online directory for doctors and lawyers that provides free rankings for 90% of the working physicians in the U.S., today revealed the most popular medical specialty categories based on Q1 2011 metrics quantifying patient participation in Avvo's online services that include searching Avvo's physician directory, asking health related questions in the Q&A forum, and submitting reviews on their doctors' Avvo profiles.

9 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Oncology News and Research

Further Reading

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Accuray acquires TomoTherapy

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

UC Davis, Jackson Laboratory and NCI partner for human clinical trials on cancer

Scientists identify potential target for reversing deadly blood infection sepsis

IASLC releases interactive staging tool in thoracic oncology

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Ambit Biosciences raises $30 million through Series D-2 equity financing

Spanish scale measures concern about cancer in healthy people

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

NKI, Agendia and MD Anderson collaborate for colorectal cancer research

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Accuray receives shareholders approval to acquire TomoTherapy

Drugs for enlarged prostate raise cancer risk

Avvo.com, cites top 10 most popular medical specialty categories based on website's patient usage

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News